Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

It’s very exciting to see that the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine schedule is being used in a large-scale study in the Democratic Republic of Congo. This is an important step towards having multiple vaccine strategies available to fight this dreadful illness, as is the recent application for marketing authorisation of this schedule by the European Medicines Agency.

These developments build on previous studies, including those conducted by Oxford Vaccine Group over the last 5 years enrolling over 200 UK participants.  These volunteers were the first to receive this vaccine anywhere in the world, and to see this altruism translate into an Ebola vaccine being used to tackle the ongoing outbreak in the DRC is a wonderful vindication of their commitment, and that of the extraordinary staff at the Oxford Vaccine Group that delivered these studies